##  [FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)](/us-en/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa-0 "FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)") 

  May 30, 2018